Fabien Zoulim

TL;DR: This Clinical Practice Guideline presents updated recommendations for the optimal management of HBV infection, and future treatment strategies to achieve 'cure' of disease and new biomarkers are discussed.

TL;DR: The objective of these EASL Clinical Practice Guidelines is to update recommendations for the optimal management of chronic hepatitis B (CHB) and the CPGs do not focus on prevention and vaccination.

TL;DR: The hepatitis B virus (HBV) genotype was determined in a total of 121 plasma samples collected in France and the US from patients chronically infected with HBV as discussed by the authors, and subsequent phylogenetic analysis of the complete genome and the individual open reading frames, showed that the virus isolate from these samples was 3248 bp long and, phylogenetically, did not cluster with any of the known genotypes.

TL;DR: New nucleoside analogues and associated compounds that are currently in preclinical or clinical development for the treatment of cancer and viral infections, and that aim to provide increased response rates and reduced side effects are reviewed.

TL;DR: cccDNA persists throughout the natural history of chronic hepatitis B, even in patients with serologic evidence of viral clearance, and long-term ADV therapy significantly decreased cccDNA levels by a primarily noncytolytic mechanism.